Personalis, Inc. PSNL
Personalis, Inc. (Nasdaq: PSNL) is an oncology diagnostics company. Its next catalyst on record is Merger with Tempus: Special stockholder meeting to vote on Merger Agreement (November 2026).
Upcoming catalysts
- November 2026Merger with Tempus — Special stockholder meeting to vote on Merger Agreement
The special meeting of our stockholders to consider and vote on the adoption of the Merger Agreement is scheduled for November 30, 2026.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NeXT Personal Dx | MRD monitoring - breast cancer | unclear | NA_NON_THERAPEUTIC |
| NeXT Personal Dx | MRD monitoring - NSCLC | unclear | NA_NON_THERAPEUTIC |
| NeXT Personal Dx | immunotherapy monitoring for late-stage solid tumors | unclear | NA_NON_THERAPEUTIC |
| NeXT Personal Dx | NAT monitoring for breast cancer | unclear | NA_NON_THERAPEUTIC |
| NeXT Dx | comprehensive tumor profiling | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.